Sydney Catalyst Boast & Toast
Sydney Catalyst Boast &
Toast is an initiative to highlight the amazing work being done by
our members. Big or small, we love hearing about the milestones and
achievements in your translational cancer research.
Each month, one
submission is included in the Sydney
Catalyst eNewsletter, and all submissions are
published on the Sydney Catalyst
website. Every six months we review all of the submissions received
and one member is awarded a prize of $2,500 to spend on
research, travel or education.
So if you have started a new
piece of work, hit a milestone, completed recruitment, been
published, or received an award, we would love to hear about it. To
enter, please complete this template and email it to us at
We hope this will be a
great chance to get word of your research out to other
Sydney Catalyst members, and
potentially more widely, and to increase opportunities for
Below are our Boast & Toast entries and round winners
Round 6: September 2016
Winning Submission in Round 6:
Melanoma translational research
achievements, Caroline Watts and Mbathio
Dieng, Cancer Epidemiology and Prevention Research
University of Sydney
Pilot and definitive randomised double-blind
placebo- controlled trials evaluating an oral cannabinoid-rich
THC/CBD cannabis extract for secondary prevention of chemotherapy
induced nausea and vomiting: The CannabisCINV study, Nicole
Wong, NHMRC CTC.
Melanoma model development and role of CD4 T cells
and B cells in cancer, Helen McGuire on behalf of T
cell Biology Program, Centenary Institute
informed choice for management of screen detected Ductal Carcinoma
in Situ (DCIS) among older women, Jolyn Hersch, Cancer
Researchers, University of Sydney/ CeMPED
Breast Cancer Research Program in Evidence Generation, Synthesis
and Translation: Enhancing Breast Screening and Staging Research to
Improve Practice, Nehmat Houssami, Sydney University
Round 5: March 2016
Submission in Round 5:
transcription factor ELF5 drives anti-estrogen therapy resistance
and metastasis in ER+ luminal breast cancer, David Gallego
Ortega and Chris Ormandy, The Kinghorn Cancer Centre, Garvan
Institute of Medical Research
Round 5 entries:
Targeting breast cancer metastasis: Delineating
the role of "Perivascular macrophages" in tumour cell
metastasis, Dr. Shweta Tikoo, Immune Imaging Program,
Centenary Institute of Cancer Medicine and Cell Biology
Breast Translational Oncology Group & The
Sydney Breast Cancer Foundation Tissue Bank, Sandra
MEOX1 and Haematopoietic Stem Cell
Induction, Georgina Hollway,
Round 4: September 2015
Submission in Round 4:
silk-based drug carriers targeted for lung cancer, Sally
Yunsun Kim, and Wojciech Chrzanowski on behalf of the Team (Kim,
S.Y., Naskar, D., Kundu, S.C., Bishop, D.P., Doble, P.A., Boddy,
A.V., Chan, H.K., Wall, I.B., Chrzanowski, W.Ch.)
Round 4 entries:
Prostate Cancer Cells to Stop them from Growing, Associate
Professor Jeff Holst, Origins of Cancer Program, Centenary
drugs in melanoma: Phase III trials in advanced melanoma,
Associate Professor Georgina Long, Melanoma Institute Australia and
The University of Sydney.
medicine for chemoresistant breast cancer through computational
modelling, Dr David Croucher, The Kinghorn Cancer Centre,
Garvan Institute of Medical Research.
Redefining the biophysical basis of MRI contrast in pre-treatment
prostate cancer assessment, Aritrick Chatterjee, Dr Roger
Bourne and team, Cancer Researchers, University of Sydney.
Spigelman classification of duodenal polyposis, Professor Allan
Spigelman, The Kinghorn Cancer Centre/St Vincent's Hospital
regulates ERBB signalling in pancreatic cancer development,
Andreia Pinho on behalf of Garvan's Pancreatic Tumourigenesis
skin cancer migration using 3D invasion systems, Nat Harris,The
Kinghorn Cancer Centre, Garvan Insitute of Medical Research.
Round 3: March 2015
Submission in Round 3:
Refer: improving patient's access to clinical
trials, Judith Trotman in collaboration with the
Haematology Clinical Research Network, NSW.
Round 3 entries:
kinase mediates enhanced inflammatory cytokine production in
glioblastoma cells expressing the mutant EGFRvIII receptor,
Fadi Gurgis and Dr Lenka Munoz, Cancer Researchers, University of
the molecular function of Inhibitor of Differentiation 4 in poor
prognosis basal-like breast cancer, Laura Baker, Dr Alexander
Swarbrick, The Kinghorn Cancer Centre, Garvan Institute of Medical
drivers of invasion & metastasis using nanotechnology, Paul
Timpson & Heidi Welsh, Garvan Institute of Medical Research
& Kinghorn Cancer Centre.
translation to clinical trial of a microRNA-based approach to the
treatment of thoracic cancers, A/Prof Glen Reid and Prof Nico
van Zandwijk, ADRI.
basis of hereditary colon cancer, Maija Kohonen-Corish,
Kinghorn Cancer Centre.
Round 2: September 2014
Submission in Round 2:
dosimetry of low energy x-ray beams,Robin Hill, Chris
Round 2 entries:
of blood vessels for control of tumor growth: role of a miRNA
vascular permeability operon, Jia Li, Vascular Biology Program,
cachexia and tumorkines, Graham Robertson, Kinghorn/Garvan.
- A randomised phase II/III trial of preoperative chemoradiotherapy
versus preoperative chemotherapy for resectable gastric cancer,
Danielle Miller, NHMRC Clinical Trials Centre
of a web-based cognitive rehabilitation programme in cancer
survivors with self-reported cognitive impairment, Victoria
Bray, Haryana Dhillon, Janette Vardy, entre for Medical Psychology
& Evidence-based Decision-making, USyd
the ability of microRNA markers in plasma to predict for docetaxel
resistance in men with castration-resistant prostate cancer, Dr
Hui-Ming Lin, Assoc Prof Lisa Horvath et al.
functional genomics to precision medicine: The therapeutic
potential of targeting Rho/ROCK signalling in pancreatic
cancer, Dr Marina Pajic, Personalised Cancer Therapeutics
Group, The Kinghorn Cancer Centre.
resonance diffusion microimaging of prostate and breast tissue,
Drs Roger Bourne, Geoff Watson, Paul Sved and team, Sydney Uni
Round 1: March 2014
Submission in Round 1:
side of Sirtuin 1 in Pancreatic Cancer, Ilse Rooman of The
Kinghorn Cancer Centre.
Round 1 entries:
evolution of hepatocellular carcinoma, Dr. Thomas Tu et al,
Development and phase I testing of a web-based intervention to
reduce anxiety and depression in survivors of testicular
cancer, Dr Louise Heiniger et al of Psycho-oncology
Co-operative Research Group (PoCoG).
evidence into practice: Implementing clinical pathways to relieve
psychological distress and improve wellbeing for cancer
patients, Dr Joanne Shaw et al, PoCoG/CemPED.
Opening, Prof. Michael Boyer, The Chris O'Brien Lifehouse
of Genetic, Environmental and Lifestyle Risk Factors to Improve
Cancer Prevention and Cancer Survivorship Outcomes, Dr. Anne
Cust, Cancer Epidemiology and Services Research.